AzaC treatment of mice that underwent a transplantation with delayed allogeneic T cells mitigates GVHD while preserving GVL. (A) Schema of the experiments. B6 mice (CD45.2) TCD BM (5 × 10⁶ cells) were used as a stem cell source. To induce GVHD, 10 × 10⁶ Tconv (B6, CD45.1) were given on day 11 after SCT followed by the treatment with AzaC or PBS (every other day; 4 doses) starting on day 15 after SCT. For examination of GVL effect, 1 × 10⁴ A20-luc/egfp leukemic cells were given along with TCD BM. (B-C) Mice treated with AzaC show significantly higher survival rate (B) and lower leukemic burden (C). Y axis in top panels indicates photon flux (photons/sec) in log scale measured from the dorsal and the ventral view with a region of interest drawn over the entire body of each mouse. Actual images of 1 representative mouse from each group are shown in bottom panels (scale: photons/sec/cm²/sr). A pool of 3 independent experiments.